On December 19th, the Chinese Center for Disease Control and Prevention released the "50th Week National Outpost Surveillance of Acute Respiratory Infectious Diseases". For two consecutive weeks, whether in southern or northern provinces, influenza virus has become the leading pathogen in the ranking of influenza like cases in emergency departments. The monitoring situation shows that acute respiratory infectious diseases are currently showing a continuous upward trend, and there are differences in the trend of infection caused by different pathogens; Influenza has entered a seasonal epidemic period, and the positive rate of influenza virus has shown a significant upward trend recently, but it is still lower than the same period last year. However, with the growing awareness of prevention over treatment and concerns about the possibility of large-scale pneumonia in the future, people's demand for popular drugs such as viral colds and respiratory diseases has also significantly increased, ushering in a peak in drug demand. Many pharmacies have also increased their sales and distribution as a result. According to our understanding, following last year's oseltamivir, this year's "flu miracle drug" Baloxavir marboxil has once again sparked a wave of drug purchases.
1:Product Introduction:
Oseltamivir is a neuraminidase inhibitor that reduces the spread of influenza A or B virus by inhibiting its release from infected cells. Oseltamivir was first launched in Switzerland in 1999 and in China in 2001, with a relatively long clinical application time.
Mabaloxavir is a novel anti influenza drug that can inhibit the endonuclease activity of polymerase acidic protein (an influenza virus specific enzyme in the RNA polymerase complex required for viral gene transcription), thereby suppressing the replication of influenza A and B viruses. Baloxavir marboxil is the first anti influenza virus drug with an innovative mechanism of action in nearly 20 years. It was first launched in Japan in 2018 and began to be used domestically in 2021.
|
|
|
| 196618-13-0 Oseltamivir | 1985606-14-1 Baloxavir marboxil |
2：Product Comparison：
one, Oseltamivir:
The instructions for this product are recommended for patients over 2 weeks of age, and the latest guidelines for pediatric influenza recommend treatment for patients of all ages. Oseltamivir has been on the market in China for a long time and is widely used in children, including newborns, infants, and young children, with good clinical experience. Based on past medical experience, we recommend starting use within 48 hours of onset, as the earlier the treatment, the better the effect. However, antiviral therapy still has clinical benefits 48 hours after the onset of flu like symptoms, and treatment usually requires continuous use for 5 days. It should be noted that for some patients, taking this medication while eating can improve tolerance. If you are using a dry suspension of finished products, it may contain sorbitol. If you have previously been a patient with genetic fructose intolerance, using it may cause indigestion and diarrhea. In addition, it often causes the following adverse reactions. For example, nausea, vomiting, headache, and pain are the most common adverse drug reactions in pediatric patients, with vomiting being the most common.
two, Mabaloxavir:
This product manual is recommended for the treatment of patients aged 5 years and above, and the latest pediatric influenza guidelines recommend the treatment of patients aged 1 year and above. Mabaloxavir was initially approved for use in children and adults aged 12 and above when it was first launched in China. In March 2023, the updated instructions can be used in children and adults aged 5 and above, so the data on its use in young children in China is limited. Currently, it is more commonly used in clinical practice for the treatment of patients aged 5 and above. Based on past medical experience, we recommend starting use within 48 hours of onset. Early treatment can achieve better clinical outcomes, but antiviral therapy still has clinical benefits 48 hours after the onset of flu like symptoms. It is also convenient to use and only needs to be taken once. However, it should be noted that this product should be avoided from being used in conjunction with foods containing multivalent cations, such as dairy products and calcium fortified beverages. Common adverse reactions of this product include diarrhea, bronchitis, nausea, sinusitis, headache, etc.
three,distinguish between :
In contrast, oseltamivir is suitable for a wider range of people, but for children under 5 years old, caution should be exercised when using Mabaroxavir according to doctor's advice. Mabaloxavir can be administered only once, improving medication adherence in pediatric patients and rapidly reducing viral load. Evidence shows that it can also reduce home transmission. And according to clinical statistical data, the incidence of nausea and vomiting adverse reactions of Mabaloxavir is significantly lower than that of Oseltamivir.
3：Summary
If a child experiences flu symptoms such as fever, cough, and fatigue, it is recommended to seek medical attention promptly and choose appropriate anti flu drugs under the guidance of a doctor.
In daily life, it is important to maintain good habits, strengthen exercise, improve children's immunity, and better cope with the flu.
Our strengths:
Our company has passed FDA and ISO19001 quality management system certification. And we have internal cooperation agreements with multiple factories and laboratories in China,Our company can provide oseltamivir powder,Mabaloxavir powder etc. at a more favorable price. If you are interested, please leave a message.
We not only have unique advantages in transportation, but also support multiple payment methods, whether you use US dollars, euros, Australian dollars, or local currencies from Singapore, Malaysia, Thailand, and so on. We can also support local currencies in these regions and countries. In addition, we also support bank cards (credit cards, etc.) for payments.
Disclaimer: The information published on this website comes from the internet, which does not mean that this website agrees with its views or confirms the authenticity of the content. Please pay attention to distinguish it. In addition, the products provided by our company are only used for scientific research. We are not responsible for the consequences of any improper use.
If you are interested in our products, or have critical suggestions on our articles or are not completely satisfied with the products received, please contact us by Email ：sales6@faithfulbio.com. Our team is committed to ensuring the complete satisfaction of customers.